PureTech Health PLC

PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group’s subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect a majority of the members of the subsidiaries’ Board of Directors. The Parent Company and Other segment represents activities that are not directly attributable to the operating segments, such as the activities of the parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Completes $68 Million Series D Financing

PureTech Founded Entity Vedanta Biosciences Completes $68 Million Series D Financing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, Inc., a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, today announced the closing of a $68 million Series D financing and provided a pipeline update. The Series D financing was led by affiliates of Magnetar Capital. Other participants in the financing were new and existing investors including Verition Fund Management, Fosun Health

Vedanta Biosciences Completes $68 Million Series D Financing

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Gelesis, the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp.

PureTech Founded Entity Gelesis, the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp.

Vor Biopharma

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vor Announces Collaboration with Janssen to Develop eHSC Transplants Combined with a Bi-Specific Antibody Therapy for AML

PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined with a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Sonde Collaborates with Qualcomm Technologies for Use of Vocal Biomarker Technology on Qualcomm Snapdragon Mobile Platforms

PureTech Founded Entity Sonde Health Announces Collaboration with Qualcomm Technologies for Use of Vocal Biomarker Technology on Qualcomm Snapdragon Mobile Platforms

BeiGene

PureTech Health plc (NASDAQ: PRTC) has announced a clinical trial and supply agreement with an affiliate of BeiGene Ltd (NASDAQ: BGNE). The partnership will evaluate BeiGene's tislelizumab, in combination with PureTech's LYT-200 for the potential treatment of difficult-to-treat solid tumor indications.

PureTech Health To Test LYT-200 / Tislelizumab Combo In Difficult To Treat Cancer

BOSTON--(BUSINESS WIRE)--PureTech Announces Clinical Trial & Supply Agreement with BeiGene to Evaluate LYT-200 & Tislelizumab in Patients with Difficult-to-Treat Solid Tumors

PureTech Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Vedanta Biosciences, announced additional results from a Phase 1 study in healthy volunteers of VE202, Vedanta's 16-strain live biotherapeutic product (LBP) candidate for inflammatory bowel disease

PureTech Founded Entity Vedanta Biosciences Announces New Data from Phase 1 Study of VE202 for the Treatment of Inflammatory Bowel Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, today announced additional results from a Phase 1 study in healthy volunteers of VE202, the Company's 16-strain live biotherapeutic product (LBP) candidate for inflammatory bowel disease (IBD). The new data were presented at the International Human Microbiome Consortium Congress 2021

Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Karuna Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers

PureTech Founded Entity Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers

Four years after launching Alivio Therapeutics, PureTech Health plc (NASDAQ: PRTC) is bringing the hydrogel player back into the fold by acquiring the remaining 22% stake of the company. Through the deal, PureTech will add Alivio's programs for inflammatory diseases to its pipeline, including LYT-500, an oral treatment for inflammatory bowel disease (IBD).

PureTech Adds Inflammatory Disease Candidates To Pipeline With Alivio Buyout

BOSTON--(BUSINESS WIRE)--PureTech Acquires Remaining Interest in Founded Entity Alivio Therapeutics

PureTech Acquires Remaining Interest in Founded Entity Alivio Therapeutics

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Gelesis Presents Findings on Plenity®-Induced Weight Loss at the AACE 2021 Annual Virtual Meeting

PureTech Founded Entity Gelesis Presents Findings on Plenity®-Induced Weight Loss at the American Association of Clinical Endocrinology (AACE) 2021 Annual Virtual Meeting

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Secures $160 Million in Financing; Poised to Deliver on the Promise of Digital Therapeutics

PureTech Founded Entity Akili Secures $160 Million in Financing; Poised to Deliver on the Promise of Digital Therapeutics

BOSTON--(BUSINESS WIRE)--PureTech to Present at the Jefferies Virtual Healthcare Conference.

PureTech to Present at the Jefferies Virtual Healthcare Conference

BOSTON--(BUSINESS WIRE)--PureTech Forms Clinical Advisory Board for Idiopathic Pulmonary Fibrosis and Related Lung Disorders

PureTech Forms Clinical Advisory Board for Idiopathic Pulmonary Fibrosis and Related Lung Disorders

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using rationally defined bacterial consortia manufactured from clonal cell banks, today announced that members of its management team will participate in the SVB Leerink Biopharma Private Company Connect Event being held virtually Thursday, May 6 - Friday, May 7, 2021. Event: SVB Leerink Biopharma Private Company Connect Event Date: Thursday, May 6 - Fr

Vedanta Biosciences to Present at the SVB Leerink Biopharma Private Company Connect Event

BOSTON--(BUSINESS WIRE)--PureTech Announces Nature Publication Supporting Modulation of Meningeal Lymphatics to Target Alzheimer's Disease Pathologies

PureTech Announces Nature Publication Supporting Modulation of Meningeal Lymphatics to Target Alzheimer's Disease Pathologies

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Gelesis Appoints Procter & Gamble Veteran Jane Wildman to Board of Directors

PureTech Founded Entity Gelesis Appoints Procter & Gamble Veteran Jane Wildman to Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using rationally defined bacterial consortia manufactured from clonal cell banks, today announced that Bernat Olle, PhD, Vedanta's Chief Executive Officer, will participate in the Executive Perspectives on Current Challenges and Opportunities for Microbiome-Based Therapeutics Panel and give a formal presentation at the 2021 Jefferies Virtual Microbiome-

Vedanta Biosciences to Present at the 2021 Jefferies Virtual Microbiome-Based Therapeutics Summit

BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2020

PureTech Announces Annual Results for Year Ended December 31, 2020

BOSTON--(BUSINESS WIRE)--PureTech Presents Promising Preclinical Data from LYT-210 Immuno-Oncology Program at American Association for Cancer Research (AACR) Annual Meeting

PureTech Presents Promising Preclinical Data from LYT-210 Immuno-Oncology Program at American Association for Cancer Research (AACR) Annual Meeting

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Akili Interactive (Akili) today announced collaborations with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to evaluate Akili digital therapeutic AK

PureTech Founded Entity Akili Collaborates with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to Study Digital Therapeutic AKL-T01 as Potential Treatment for Patients with COVID Brain Fog

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Announces the Results of EndeavorRx™ Clinical Study in Pediatric ADHD Published in Nature Digital Medicine

PureTech Founded Entity Akili Announces the Results of EndeavorRx™ Clinical Study in Pediatric ADHD Published in Nature Digital Medicine

BOSTON--(BUSINESS WIRE)--PureTech announces Stephen Muniz, Esq., will retire from his role as Chief Operating Officer and will step down from the Board Of Directors.

News for PureTech Health PLC Stock (PRTC)